SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study

SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study

In clinical trials, a sofosbuvir/velpatasvir (SOF/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. No real-life data on genotype 3 (GT3) cirrhotic pat...

Full description

Bibliographic Details
Main Authors: Alessandra Mangia, Giovanni Cenderello, Massimiliano Copetti, Gabriella Verucchi, Valeria Piazzolla, Celeste Lorusso, Rosanna Santoro, Maria Maddalena Squillante, Alessandra Orlandini, Rosalba Minisini, Alessia Ciancio
Format: Article
Language:English
Published: MDPI AG 2019-04-01
Series:Cells
Subjects:
HCV
SOF/VEL
genotype 3
cirrhosis
portal hypertension
Online Access:https://www.mdpi.com/2073-4409/8/4/313

Internet

https://www.mdpi.com/2073-4409/8/4/313

Similar Items